With core business clearly deteriorating, Abercrombie & Fitch Co. ANF 2.4% bulls have been shifting their attention to recent market buyout rumors. Unfortunately, the M&A route may be a dead-end for Abercrombie as well, Morgan Stanley analyst Kimberly Greenberger said.

President Donald Trump has taken fire from critics in recent weeks following his firing of FBI head James Comey. While Democrats and even some Republicans are calling for a Trump impeachment, investors are trying to figure out what, if any, impact the recent developments will have on the Republican agenda of healthcare reform, tax reform…

This week, bitcoin enthusiasts and investors celebrated Bitcoin Pizza Day, the seven-year anniversary of the day programmer Laszlo Hanyecz spent 10,000 bitcoin on two Papa John’s Int’l, Inc. PZZA 0.55% pizzas. Today, the bitcoin spent on those pizzas would be worth $22 million.

Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment candidate, Roclatan. According to the company, Roclatan achieved the primary efficacy endpoint in demonstrating superiority over both latanoprost and Rhopressa.

Puma Biotechnology Inc PBYI 0.37% investors got some major vindication Wednesday when the FDA’s Oncologic Drugs Advisory Committee voted 12–4 to recommend approval of neratinib for treatment of patients with early-stage HER2-positive breast cancer. Puma had plenty of doubters and short sellers out there, which have only fueled the stock’s massive 105-percent gain this week.

The news just keeps getting better for NVIDIA Corporation NVDA 0.5% investors. After a huge Q1 earnings beat sent shares soaring, Bloomberg reported Wednesday that the Japanese telecom giant SoftBank Corp has taken a $4 billion stake in Nvidia.

Puma Biotechnology Inc PBYI 0.37% traders are eagerly-anticipating the end of the trading halt for Puma on Wednesday after the company received a positive recommendation for approval of neratinib from the FDA’s Oncologic Drugs Advisory Committee.

Bank investors hoping financial deregulation will open the door for a new golden era of banking in the near future will likely have to be patient and keep expectations in check.

Biotech investors may have noticed that the first quarter of the year is a bit sluggish for drug sales. They aren’t imagining things, according to Bernstein analyst Aaron Gal.

Rumors of a potential GPU licensing deal between Advanced Micro Devices, Inc. AMD 0.27% and Intel Corporation INTC 0.55% may finally be over.